346 related articles for article (PubMed ID: 17495322)
1. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
2. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
Medicherla S; Reddy M; Ying J; Navas TA; Li L; Nguyen AN; Kerr I; Hanjarappa N; Protter AA; Higgins LS
Anticancer Res; 2008; 28(6A):3827-33. PubMed ID: 19189670
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
5. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
6. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
7. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Vanderkerken K; De Leenheer E; Shipman C; Asosingh K; Willems A; Van Camp B; Croucher P
Cancer Res; 2003 Jan; 63(2):287-9. PubMed ID: 12543775
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
9. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.
Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
Biochem Biophys Res Commun; 2004 Apr; 316(3):859-66. PubMed ID: 15033480
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.
Van Valckenborgh E; Croucher PI; De Raeve H; Carron C; De Leenheer E; Blacher S; Devy L; Noël A; De Bruyne E; Asosingh K; Van Riet I; Van Camp B; Vanderkerken K
Am J Pathol; 2004 Sep; 165(3):869-78. PubMed ID: 15331411
[TBL] [Abstract][Full Text] [Related]
11. The 5T2MM murine model of multiple myeloma: maintenance and analysis.
Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B
Methods Mol Med; 2005; 113():191-205. PubMed ID: 15968104
[TBL] [Abstract][Full Text] [Related]
12. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
[TBL] [Abstract][Full Text] [Related]
13. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.
Vanderkerken K; De Greef C; Asosingh K; Arteta B; De Veerman M; Vande Broek I; Van Riet I; Kobayashi M; Smedsrod B; Van Camp B
Br J Cancer; 2000 Feb; 82(4):953-9. PubMed ID: 10732771
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
15. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss.
Böhm C; Hayer S; Kilian A; Zaiss MM; Finger S; Hess A; Engelke K; Kollias G; Krönke G; Zwerina J; Schett G; David JP
J Immunol; 2009 Nov; 183(9):5938-47. PubMed ID: 19828631
[TBL] [Abstract][Full Text] [Related]
16. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
Menu E; Asosingh K; Indraccolo S; De Raeve H; Van Riet I; Van Valckenborgh E; Vande Broek I; Fujii N; Tamamura H; Van Camp B; Vanderkerken K
Haematologica; 2006 May; 91(5):605-12. PubMed ID: 16627256
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
18. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C
Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670
[TBL] [Abstract][Full Text] [Related]
19. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Edwards CM; Mueller G; Roelofs AJ; Chantry A; Perry M; Russell RG; Van Camp B; Guyon-Gellin Y; Niesor EJ; Bentzen CL; Vanderkerken K; Croucher PI
Int J Cancer; 2007 Apr; 120(8):1657-63. PubMed ID: 17230522
[TBL] [Abstract][Full Text] [Related]
20. Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells.
Libouban H; Onno C; Pascaretti-Grizon F; Gallois Y; Moreau MF; Baslé MF; Chappard D
Leuk Res; 2006 Nov; 30(11):1371-5. PubMed ID: 16814861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
